Aubrey S Smith
Overview
Explore the profile of Aubrey S Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rangel Rivera G, Dwyer C, Knochelmann H, Smith A, Aksoy B, Cole A, et al.
Cancer Res
. 2023 Oct;
84(1):69-83.
PMID: 37801615
Significance: Elevating T-cell stemness by progressively blocking PI3Kδ signaling during ex vivo manufacturing of adoptive cell therapies alters metabolic and functional properties to enhance antitumor immunity dependent on Tcf1 and...
2.
Wyatt M, Huff L, Nelson M, Neal L, Medvec A, Rangel Rivera G, et al.
Mol Ther
. 2023 Apr;
31(7):2120-2131.
PMID: 37081789
IL-17-producing antigen-specific human T cells elicit potent antitumor activity in mice. Yet, refinement of this approach is needed to position it for clinical use. While activation signal strength regulates IL-17...
3.
Rangel Rivera G, Dwyer C, Knochelmann H, Smith A, Aksoy A, Cole A, et al.
bioRxiv
. 2023 Mar;
PMID: 36945574
Generating stem memory T cells (T ) is a key goal for improving cancer immunotherapy. Yet, the optimal way to modulate signaling pathways that enrich T properties remains elusive. Here,...
4.
Camargo C, Muhuri A, Alapan Y, Sestito L, Khosla M, Manspeaker M, et al.
Cell Rep
. 2023 Feb;
42(3):112175.
PMID: 36848287
CD8 T cell recruitment to the tumor microenvironment is critical for the success of adoptive cell therapy (ACT). Unfortunately, only a small fraction of transferred cells home to solid tumors....
5.
Smith A, Knochelmann H, Wyatt M, Rangel Rivera G, Rivera-Reyes A, Dwyer C, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35017148
Background: Adoptive T cell transfer (ACT) therapy improves outcomes in patients with advanced malignancies, yet many individuals relapse due to the infusion of T cells with poor function or persistence....
6.
Park M, Zhang L, Min K, Cho J, Yeh C, Moon H, et al.
Cell Metab
. 2021 Dec;
33(12):2380-2397.e9.
PMID: 34879239
Accelerated glycolysis is the main metabolic change observed in cancer, but the underlying molecular mechanisms and their role in cancer progression remain poorly understood. Here, we show that the deletion...
7.
Knochelmann H, Rivera-Reyes A, Wyatt M, Smith A, Chamness R, Dwyer C, et al.
Oncoimmunology
. 2021 Aug;
10(1):1959101.
PMID: 34408920
Adoptive transfer of tumor-infiltrating lymphocytes (TIL) elicits the regression of metastatic malignancies, yet a low proportion of patients achieve complete durable responses. The high incidence of relapse in these patients...
8.
Rangel Rivera G, Knochelmann H, Dwyer C, Smith A, Wyatt M, Rivera-Reyes A, et al.
Front Immunol
. 2021 Apr;
12:645242.
PMID: 33815400
Emerging reports show that metabolic pathways can be targeted to enhance T cell-mediated immunity to tumors. Yet, tumors consume key metabolites in the host to survive, thus robbing T cells...
9.
Knochelmann H, Dwyer C, Smith A, Bowers J, Wyatt M, Nelson M, et al.
Cancer Res
. 2020 Jun;
80(18):3920-3932.
PMID: 32561531
The accessibility of adoptive T-cell transfer therapies (ACT) is hindered by the cost and time required for product development. Here we describe a streamlined ACT protocol using Th17 cells expanded...
10.
Dwyer C, Arhontoulis D, Rangel Rivera G, Knochelmann H, Smith A, Wyatt M, et al.
Eur J Immunol
. 2020 May;
50(9):1386-1399.
PMID: 32383488
Adoptive T cell transfer therapy induces objective responses in patients with advanced malignancies. Despite these results, some individuals do not respond due to the generation of terminally differentiated T cells...